Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoft has received expanded clearance from the FDA for the Axxent Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings.
Subscribe to our email newsletter
The Axxent System which was previously cleared for accelerated treatment of early stage breast cancer is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.
As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.
Michael Klein, president and CEO of Xoft, said: “The clearance serves as the foundation for Xoft’s expansion into new treatment areas beyond breast cancer and fuels the continued market adoption and expansion of this important technology.”